Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiongdan Wan is a traditional Chinese medicine (TCM) formulation primarily composed of bear gall (Xiongdan), which contains high concentrations of bile acids such as tauroursodeoxycholic acid (TUDCA) and ursodeoxycholic acid (UDCA). Traditionally utilized in Chinese medicine for its ability to clear heat, detoxify, and improve vision, it is currently being evaluated as a monotherapy for Major Depressive Disorder (MDD) in clinical trials led by the Shanghai Mental Health Center. The drug's potential antidepressant mechanism is thought to involve neuroprotective effects, reduction of endoplasmic reticulum stress, and modulation of the hypothalamic-pituitary-adrenal (HPA) axis, possibly through the activation of the TGR5 receptor and the BDNF/TrkB signaling pathway.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xiongdan wan (Shanghai Mental Health Center).